Genotyping cytomegalovirus UL97 mutations by high-resolution melting analysis with unlabeled probe
- 247 Downloads
Human cytomegalovirus (CMV) is an opportunistic pathogen, and infections with this virus can be treated with ganciclovir (GCV). Most GCV-resistant clinical CMV isolates contain a mutation in the UL97 gene. Genotypic assays for diagnostic screening of GCV-resistant CMV have been developed. High-resolution melting analysis (HRMA) with unlabeled probe is considered a perfect tool for this purpose. In this study, we have developed an HRMA-based genotypic test for the detection of UL97 mutations. Wild type and M460V/I mutants of UL97 were constructed. HRMA with unlabeled probe was used as a genotyping method for the detection of M460V/I mutations. The melting peaks obtained directly from PCR products did not enable us to distinguish the wild type from M460 mutants. The sensitivity and accuracy of HRMA were dramatically improved by using unlabeled probe. HRMA with unlabeled probe successfully distinguished M460V from M460I and served well for the detection of M460V/I mutations in clinical samples. HRMA with unlabeled probe proves to be a sensitive and cost-effective genotyping method for the detection of M460 mutations.
The study was supported by research grants from the Shenzhen Science and Technology Project. We thank Shenzhen Biomedical Research Support Platform for technical help.
Conflict of interest
- 1.Baldanti F, Underwood MR, Talarico CL, Simoncini L, Sarasini A, Biron KK, Gerna G (1998) The Cys607–>Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients. Antimicrob Agents Chemother 42:444–446PubMedGoogle Scholar
- 2.Baldanti F, Michel D, Simoncini L, Heuschmid M, Zimmermann A, Minisini R, Schaarschmidt P, Schmid T, Gerna G, Mertens T (2002) Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system. Antiviral Res 54:59–67PubMedCrossRefGoogle Scholar
- 3.Biron KK, Fyfe JA, Stanat SC, Leslie LK, Sorrell JB, Lambe CU, Coen DM (1986) A human cytomegalovirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc Natl Acad Sci USA 83:8769–8773PubMedCrossRefGoogle Scholar
- 7.Chou S, Erice A, Jordan MC, Vercellotti GM, Michels KR, Talarico CL, Stanat SC, Biron KK (1995) Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 171:576–583PubMedCrossRefGoogle Scholar
- 15.Drew WL, Ives D, Lalezari JP, Crumpacker C, Follansbee SE, Spector SA, Benson CA, Friedberg DN, Hubbard L, Stempien MJ et al (1995) Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS: Syntex Cooperative Oral Ganciclovir Study Group. N Engl J Med 333:615–620PubMedCrossRefGoogle Scholar
- 23.Kampmann SE, Schindele B, Apelt L, Buhrer C, Garten L, Weizsaecker K, Kruger DH, Ehlers B, Hofmann J (2011) Pyrosequencing allows the detection of emergent ganciclovir resistance mutations after HCMV infection. Med Microbiol ImmunolGoogle Scholar
- 24.Landry ML, Stanat S, Biron K, Brambilla D, Britt W, Jokela J, Chou S, Drew WL, Erice A, Gilliam B, Lurain N, Manischewitz J, Miner R, Nokta M, Reichelderfer P, Spector S, Weinberg A, Yen-Lieberman B, Crumpacker C (2000) A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob Agents Chemother 44:688–692PubMedCrossRefGoogle Scholar
- 27.Michel D, Schaarschmidt P, Wunderlich K, Heuschmid M, Simoncini L, Muhlberger D, Zimmermann A, Pavic I, Mertens T (1998) Functional regions of the human cytomegalovirus protein pUL97 involved in nuclear localization and phosphorylation of ganciclovir and pUL97 itself. J Gen Virol 79(Pt 9):2105–2112PubMedGoogle Scholar